These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 17503753

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
    Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Järvinen A, Ristola M, Yki-Järvinen H.
    Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
    [Abstract] [Full Text] [Related]

  • 3. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J.
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [Abstract] [Full Text] [Related]

  • 4. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
    Schindler K, Rieger A, Tura A, Gmeinhardt B, Touzeau-Römer V, Haider D, Pacini G, Ludvik B.
    Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
    [Abstract] [Full Text] [Related]

  • 5. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices.
    McComsey GA, O'Riordan M, Setzer B, Lebrecht D, Baron E, Walker UA.
    Eur J Clin Nutr; 2008 Aug; 62(8):1031-7. PubMed ID: 17538545
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
    Valantin MA, Lanoy E, Bentata M, Kalmykova O, Boutekadjirt A, Allavena C, Rozenbaum W, Peytavin G, Amellal B, Calvez V, Costagliola D, Katlama C, NoNuke ANRS 108 Study Team.
    HIV Med; 2008 Oct; 9(8):625-35. PubMed ID: 18624724
    [Abstract] [Full Text] [Related]

  • 9. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).
    Slama L, Lanoy E, Valantin MA, Bastard JP, Chermak A, Boutekatjirt A, William-Faltaos D, Billaud E, Molina JM, Capeau J, Costagliola D, Rozenbaum W.
    Antivir Ther; 2008 Oct; 13(1):67-76. PubMed ID: 18389900
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E, Miró O, Rodríguez-Santiago B, Garrabou G, Estany C, Masabeu A, Force L, Barrufet P, Cucurull J, Domingo P, Alonso-Villaverde C, Bonjoch A, Morén C, Pérez-Alvarez N, Clotet B, MULTINEKA Study Group.
    Clin Infect Dis; 2009 Sep 15; 49(6):892-900. PubMed ID: 19663689
    [Abstract] [Full Text] [Related]

  • 12. Antiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutrition.
    Maia BS, Engelson ES, Wang J, Kotler DP.
    Clin Nutr; 2005 Dec 15; 24(6):971-8. PubMed ID: 16095765
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.
    Moreno-Torres A, Domingo P, Pujol J, Blanco-Vaca F, Arroyo JA, Sambeat MA.
    Antivir Ther; 2007 Dec 15; 12(2):195-203. PubMed ID: 17503662
    [Abstract] [Full Text] [Related]

  • 15. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sevastianova K, Sutinen J, Kannisto K, Hamsten A, Ristola M, Yki-Järvinen H.
    Am J Physiol Endocrinol Metab; 2008 Jul 15; 295(1):E85-91. PubMed ID: 18430964
    [Abstract] [Full Text] [Related]

  • 16. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study.
    Rabing Christensen E, Stegger M, Jensen-Fangel S, Laursen AL, Ostergaard L.
    Clin Infect Dis; 2004 Nov 01; 39(9):1371-9. PubMed ID: 15494915
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy.
    Sutinen J, Kannisto K, Korsheninnikova E, Fisher RM, Ehrenborg E, Nyman T, Virkamäki A, Funahashi T, Matsuzawa Y, Vidal H, Hamsten A, Yki-Järvinen H.
    Am J Physiol Endocrinol Metab; 2004 Jun 01; 286(6):E941-9. PubMed ID: 14749206
    [Abstract] [Full Text] [Related]

  • 19. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.
    Yki-Järvinen H, Sutinen J, Silveira A, Korsheninnikova E, Fisher RM, Kannisto K, Ehrenborg E, Eriksson P, Hamsten A.
    Arterioscler Thromb Vasc Biol; 2003 Apr 01; 23(4):688-94. PubMed ID: 12615670
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.